한글목차

세계 호흡기 바이러스 백신 시장의 미래는 클리닉, 병원, 진료소, 약국 및 상점 시장에서의 기회가 유망합니다. 세계 호흡기 바이러스 백신 시장은 2025-2031년 7.4%의 연평균 복합 성장률(CAGR)로 2031년까지 약 145억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 호흡기 바이러스 감염률 증가, 백신의 이점에 대한 인식 증가, 백신 개발 가속화 및 보급을 위한 정부 지출 증가입니다.

• Lucintel의 예측에 따르면 백신 유형별로는 강력하고 지속적인 면역반응을 자극하는 불활성화/키드백신이 예측 기간 중 가장 높은 성장세를 보일 것으로 예상됩니다.
• 최종 용도 부문에서는 병원이 예측 기간 중 가장 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 북미가 강력한 의료 인프라와 정부 자금 지원으로 인해 예측 기간 중 가장 높은 성장률을 보일 것으로 예상됩니다.

호흡기 바이러스 백신 시장의 전략적 성장 기회

호흡기 바이러스 백신 시장은 백신 기술의 발전, 수요 증가, 공중보건 우선순위의 변화 등을 배경으로 주요 용도에서 몇 가지 전략적 성장 기회를 제공합니다.

• 혼합 백신: 여러 호흡기 바이러스를 예방하는 혼합 백신의 개발은 큰 성장 기회가 될 수 있습니다. 이 접근법은 예방접종 일정을 간소화하여 전체 백신 접종률을 향상시킬 수 있습니다.
• mRNA 백신 기술: 호흡기 바이러스 백신에 mRNA 기술을 활용하는 것은 성장 잠재력을 가지고 있습니다. 그 유연성과 신속한 개발 능력은 새로운 호흡기 위협에 대응하는 데 있으며, 가치가 있습니다.
• 범용 백신: 범용 호흡기 바이러스 백신 연구에 투자함으로써 시장을 발전시킬 수 있습니다. 이러한 백신은 광범위한 방어력을 제공하고 여러 백신의 필요성을 줄일 수 있습니다.
• 첨단 전달 방법: 비강주사제, 마이크로니들 패치 등 예방접종 전달을 위한 새로운 접근법을 모색하는 것은 성장 분야입니다. 이를 통해 백신의 투여 방식과 환자 수용도를 개선할 수 있습니다.
• 시장 접근성 확대: 백신에 대한 접근성이 부족한 시장과 신흥 시장에서의 백신 접근성 향상은 시장 확대의 큰 기회입니다. 유통망 강화와 현지 생산을 통해 백신의 가용성 및 적용 범위에 대한 격차를 해소할 수 있습니다.

이러한 요인들은 호흡기 바이러스 백신 시장의 기술 혁신을 촉진하고, 적용 범위를 확대하며, 백신에 대한 접근을 용이하게 할 것입니다. 이는 호흡기 바이러스 발생에 효과적으로 대응하는 동시에 전 세계 보건 성과를 개선하는 데 있으며, 특히 필수적입니다.

호흡기 바이러스 백신 시장 성장 촉진요인 및 과제

기술 발전, 경제적 결정 요인, 규제 문제 등 다양한 요인이 호흡기 바이러스 백신 시장을 촉진하거나 저해하는 요인이 있습니다. 이러한 요인을 이해하는 것은 시장 개발에 필수적입니다.

호흡기 바이러스 백신 시장 성장 촉진요인은 다음과 같습니다. :

• 기술 발전: 기술 발전: mRNA 백신, 혼합 백신 등 백신 기술 혁신이 시장 성장을 촉진할 것입니다. 이러한 발전은 신종 바이러스에 대한 백신의 효능, 안전성, 유연성을 향상시킵니다.
• 백신 수요 증가: 호흡기 바이러스의 급격한 증가는 공중보건 캠페인의 지속과 함께 백신 수요를 자극하고 있습니다. 이에 따라 백신 개발 및 생산에 대한 투자가 증가하고 있습니다.
• 정부 지원: 정부의 지원 정책과 잠재적 유통 채널에 대한 연구 자금 지원은 주요 촉진요인입니다. 정부 구상은 백신의 접근성을 촉진하고 공중 보건 목표를 지원합니다.
• 백신 접근성 확대: 유통 시스템 개선과 백신 생산 능력의 향상으로 백신 접근성이 부족한 지역에 대한 접근성이 확대되고 있습니다. 이는 지역 간 격차를 해소하고 더 많은 사람들이 예방접종 프로그램의 혜택을 받을 수 있도록 돕습니다.
• 연구개발(R&D) : 지속적인 연구개발 활동은 백신 기술 및 공급 방법의 혁신에 필수적입니다. 이러한 연구개발 없이는 새로운 백신의 개발이나 기존 백신의 개선은 불가능합니다.

호흡기 바이러스 백신 시장이 해결해야 할 과제는 다음과 같습니다. :

• 규제적 장애물: 백신 승인에 필요한 복잡한 규제 요건을 통과하는 것은 어려운 일입니다. 국제 표준을 준수하는 것은 프로세스를 복잡하게 만들고 시장 진입에 영향을 미칩니다.
• 높은 비용: 백신 개발 및 제조와 관련된 높은 비용으로 인해 백신 가격의 경제성을 저해할 수 있습니다. 이 문제는 특히 백신을 구하기 어려운 저자원 국가에서 더욱 심각합니다.
• 백신에 대한 거부감: 백신 접종에 대한 거부감을 없애고 잘못된 정보에 대처하는 것은 백신 접종률을 높이는 데 도움이 됩니다. 백신 접종에 대한 장벽을 없애기 위해서는 대중 교육 캠페인이 필수적입니다.

이러한 촉진요인과 과제는 호흡기 바이러스 백신 시장의 혁신, 접근성, 공중보건 노력에 큰 영향을 미칩니다. 이러한 요인들을 해결하면 백신 개발, 유통, 그리고 사람들의 전반적인 건강 상태를 개선할 수 있습니다.

목차

제1장 개요

제2장 세계의 호흡기 바이러스 백신 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 호흡기 바이러스 백신 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 호흡기 바이러스 백신 시장 : 유형별
  • 불활성화/살균
  • 약독생
  • 재조합
• 세계의 호흡기 바이러스 백신 시장 : 투여 경로별
  • 근육내
  • 비강내
  • 피하
• 세계의 호흡기 바이러스 백신 시장 : 적응증별
  • 인플루엔자
  • 홍역
  • 볼거리와 풍진
  • 코로나바이러스
• 세계의 호흡기 바이러스 백신 시장 : 최종 용도별
  • 개업의
  • 병원
  • 클리닉
  • 약국/점포
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 호흡기 바이러스 백신 시장 : 지역별
• 북미의 호흡기 바이러스 백신 시장
• 유럽의 호흡기 바이러스 백신 시장
• 아시아태평양의 호흡기 바이러스 백신 시장
• 기타 지역의 호흡기 바이러스 백신 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 호흡기 바이러스 백신 시장의 성장 기회 : 유형별
  • 세계의 호흡기 바이러스 백신 시장의 성장 기회 : 투여 경로별
  • 세계의 호흡기 바이러스 백신 시장의 성장 기회 : 적응증별
  • 세계의 호흡기 바이러스 백신 시장의 성장 기회 : 최종 용도별
  • 세계의 호흡기 바이러스 백신 시장의 성장 기회 : 지역별
• 세계의 호흡기 바이러스 백신 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 호흡기 바이러스 백신 시장의 생산능력 확대
  • 세계의 호흡기 바이러스 백신 시장에서의 기업인수합병(M&A), 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 개요

• Sanofi
• AstraZeneca
• Merck
• GlaxoSmithKline
• Serum Institute of India
• Moderna
• Bavarian Nordic

영문목차

The future of the global respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets. The global respiratory virus vaccine market is expected to reach an estimated $14.5 billion by 2031 with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the rising rate of respiratory viral infections, growing awareness of the benefits of vaccines, and increasing government spending to fast-track the development of vaccines and ensure widespread access.

• Lucintel forecasts that, within the type category, inactivated/killed is expected to witness the highest growth over the forecast period due to their ability to stimulate a powerful and enduring immune response.
• Within the end-use category, the hospital is expected to witness the highest growth over the forecast period.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to its strong healthcare infrastructure and government funding.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Respiratory Virus Vaccine Market

The market for vaccines against respiratory viruses is transforming due to several key trends driven by technological advancements and changes in public health demands. These developments have defined the future of preventing respiratory viruses.

• Combination Vaccines: More attention is now being directed toward the development of vaccines that can protect against multiple respiratory infections, such as flu, COVID-19, and RSV. The purpose of combination vaccines is to simplify vaccination schedules and increase compliance.
• mRNA Technology: mRNA technology is not only meant for COVID-19 vaccinations. Researchers are also investigating its potential application in developing vaccines targeting different respiratory viral diseases, thus offering swift development and adaptability to new strains.
• Universal Respiratory Virus Vaccines: Attempts are being made to design universal vaccines that can offer broad protection against many kinds of respiratory viruses. By reducing the need for multiple shots, these universal vaccines can improve overall health outcomes in communities.
• Enhanced Delivery Methods: Research is being conducted on utilizing nasal sprays and microneedle patches, among other delivery methods, aiming to improve ease of administration as well as patient acceptance. These methods aim to increase vaccination rates and accessibility.
• Global Collaboration: Faster development and distribution of vaccines against respiratory viruses have been facilitated through increased international collaboration. Global partnerships seek to share research findings, resources, and distribution networks that better position everyone involved in addressing respiratory infections globally.

These trends focus on improving vaccine technology, broadening protection coverage, and enhancing delivery mechanisms, thereby altering the landscape of the respiratory virus vaccine market. They are necessary for tackling emerging threats from viruses causing respiratory illnesses while also positively influencing overall community well-being.

Recent Developments in the Respiratory Virus Vaccine Market

Advancements in the respiratory virus vaccine market are characterized by significant milestones involving the adoption of new technologies and approaches to enhance the effectiveness and accessibility of vaccines. Recent advancements have focused on increasing protection and managing emerging viral threats.

• Combination Vaccine Development: Ongoing efforts are aimed at developing combination vaccines that address influenza, COVID-19, and other respiratory viruses. The main aim of these vaccines is to simplify vaccination schedules and enhance overall immunity.
• Universal Vaccine Research: Progress is being made in research aimed at producing universal vaccines that can protect against various respiratory viruses. Such vaccines could lessen the need for multiple shots and offer more complete protection.
• Improved Vaccine Delivery: Innovations are being made regarding how vaccines will be administered, such as nasal sprays and microneedle patches. These methods seek to improve vaccine compliance among patients while ensuring better delivery procedures.
• Increased Production Capacity: Scaling up production capacity for vaccines, particularly in emerging markets, is critical in meeting growing demand and achieving equal distribution of vaccines.

These developments significantly influence the respiratory virus vaccine market through technological improvements, better delivery options, and increased manufacturing capacities, which are essential for improving global responses to viral threats to public health.

Strategic Growth Opportunities for Respiratory Virus Vaccine Market

The respiratory virus vaccine market distinctly offers several strategic growth opportunities across important applications, driven by advancements in vaccine technology, increasing demand, and shifting public health priorities.

• Combination Vaccines: Developing combination vaccines that protect against numerous respiratory viruses creates a significant growth opportunity. Streamlining immunization schedules through this approach improves overall vaccine uptake.
• mRNA Vaccine Technology: Utilizing mRNA technology for respiratory virus vaccines has growth potential. It is valuable for addressing emerging respiratory threats due to its flexibility and quick development capabilities.
• Universal Vaccines: Investing in universal respiratory virus vaccine research can propel the market forward. These vaccines could provide broad protection and reduce the need for multiple vaccines.
• Advanced Delivery Methods: Exploring new approaches to delivering vaccinations, including nasal sprays and microneedle patches, represents areas of growth. These will improve how the vaccine is administered and how it is accepted by patients.
• Expanded Market Access: Improving access to vaccines in underserved and emerging markets is a major opportunity for expansion. Enhanced distribution networks and local production can bridge gaps related to vaccine availability and coverage.

These factors are shaping the respiratory virus vaccine market by spurring innovation and extending coverage while making vaccines easily accessible to users. They are particularly essential in improving global health performance while effectively responding to respiratory virus incidences.

Respiratory Virus Vaccine Market Driver and Challenges

Various factors drive or hinder the respiratory virus vaccine market, including technological advancements, economic determinants, and regulatory issues. Understanding these components is critical for market development.

The factors responsible for driving the respiratory virus vaccine market include:

• Technological Advancements: Innovation in vaccine technology, such as mRNA and combination vaccines, boosts market growth. These advancements enhance the efficacy, safety, and flexibility of vaccines against new strains of viruses.
• Increased Demand for Vaccines: The surging prevalence of respiratory viruses, coupled with ongoing public health campaigns, stimulates demand for vaccines. This has resulted in increased investments in vaccine development and production.
• Government Support: Supportive government policies and financing for research on potential distribution channels are key drivers. Government initiatives promote the accessibility of vaccines and support public health goals.
• Expanded Vaccine Access: Better distribution systems and increased vaccine manufacturing capacity have expanded access to underserved areas. This helps to bridge gaps between communities while ensuring that more people are covered by immunization programs.
• Research and Development (R&D): Continuous R&D activities are crucial for innovations in vaccine technology and delivery methods. Without this kind of research, no new vaccines can be developed or improvements made to existing ones.

Challenges in the respiratory virus vaccine market include:

• Regulatory Hurdles: Navigating complex regulatory requirements for vaccine approval may be challenging. Conforming to international standards complicates the process and affects market entry.
• High Costs: Affordability could be hampered by high costs associated with developing and producing vaccines. This problem is particularly relevant in low-resource countries where vaccine availability is limited.
• Vaccine Hesitancy: Combatting hesitancy toward vaccination and addressing misinformation can help raise vaccination rates. Public education campaigns are essential to eliminate barriers to vaccine acceptance.

These drivers and challenges significantly impact innovation, access, and public health efforts in the respiratory virus vaccine market. By addressing these factors, it is possible to improve vaccine development, distribution, and the overall health status of the population.

List of Respiratory Virus Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies respiratory virus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory virus vaccine companies profiled in this report include-

• Sanofi
• AstraZeneca
• Merck
• GlaxoSmithKline
• Serum Institute of India
• Moderna
• Bavarian Nordic

Respiratory Virus Vaccine by Segment

The study includes a forecast for the global respiratory virus vaccine market by type, route of administration, indication, end use, and region.

Respiratory Virus Vaccine Market by Type [Analysis by Value from 2019 to 2031]:

• Inactivated/Killed
• Live-Attenuated
• Recombinant

Respiratory Virus Vaccine Market by Route of Administration [Analysis by Value from 2019 to 2031]:

• Intramuscular
• Intranasal
• Subcutaneous

Respiratory Virus Vaccine Market by Indication [Analysis by Value from 2019 to 2031]:

• Influenza
• Measles
• Mumps & Rubella
• Coronavirus

Respiratory Virus Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Physician Offices
• Hospitals
• Clinics
• Pharmacies/Stores
• Others

Respiratory Virus Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Respiratory Virus Vaccine Market

The market for respiratory virus vaccines is experiencing significant advancements driven by new pathogens, technologies, and changing public health needs. Improvements in the United States, China, Germany, India, and Japan indicate worldwide efforts toward better vaccine efficacy and availability against respiratory viral threats.

• U.S.: Updated vaccines against various respiratory viruses, including novel variants of influenza and RSV, have recently been approved in the U.S. The focus is on developing combined vaccines that work against different pathogens simultaneously to make immunization schedules more efficient.
• China: To curb the increasing number of respiratory virus infections, China's respiratory virus vaccine portfolio is advancing with innovative options for COVID-19 and influenza. Broader immunity coverage through a variety of strains is also a focus, while accessibility in urban cities and rural areas has been optimized.
• Germany: Germany is investing in next-generation respiratory virus vaccines, which include those with improved efficacy against seasonal flu and emerging respiratory viruses. Additionally, investment is directed toward mRNA vaccine technology for wider applications.
• India: The country is beginning to increase production capacity for respiratory virus vaccines, addressing the rising demand for COVID-19 and seasonal flu vaccines. Public health campaigns are being intensified to improve vaccination coverage in underserved regions.
• Japan: Advanced vaccinations offering prolonged protection and minimal side effects are currently being developed in Japan. Equally important are studies pursuing non-injectable administration modes for increased acceptance and convenience for the population.

Features of the Global Respiratory Virus Vaccine Market

Market Size Estimates: Respiratory virus vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Respiratory virus vaccine market size by various segments, such as by type, route of administration, indication, end use, and region in terms of ($B).

Regional Analysis: Respiratory virus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, route of administrations, indications, end uses, and regions for the respiratory virus vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory virus vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the respiratory virus vaccine market by type (inactivated/killed, live-attenuated, and recombinant), route of administration (intramuscular, intranasal, and subcutaneous), indication (influenza, measles, mumps & rubella, and coronavirus), end use (physician offices, hospitals, clinics, pharmacies/stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Respiratory Virus Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Respiratory Virus Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Respiratory Virus Vaccine Market by Type
  • 3.3.1: Inactivated/Killed
  • 3.3.2: Live-Attenuated
  • 3.3.3: Recombinant
• 3.4: Global Respiratory Virus Vaccine Market by Route of Administration
  • 3.4.1: Intramuscular
  • 3.4.2: Intranasal
  • 3.4.3: Subcutaneous
• 3.5: Global Respiratory Virus Vaccine Market by Indication
  • 3.5.1: Influenza
  • 3.5.2: Measles
  • 3.5.3: Mumps & Rubella
  • 3.5.4: Coronavirus
• 3.6: Global Respiratory Virus Vaccine Market by End Use
  • 3.6.1: Physician Offices
  • 3.6.2: Hospitals
  • 3.6.3: Clinics
  • 3.6.4: Pharmacies/Stores
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Respiratory Virus Vaccine Market by Region
• 4.2: North American Respiratory Virus Vaccine Market
  • 4.2.1: North American Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.2.2: North American Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.3: European Respiratory Virus Vaccine Market
  • 4.3.1: European Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.3.2: European Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.4: APAC Respiratory Virus Vaccine Market
  • 4.4.1: APAC Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.4.2: APAC Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.5: ROW Respiratory Virus Vaccine Market
  • 4.5.1: ROW Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.5.2: ROW Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Indication
  • 6.1.4: Growth Opportunities for the Global Respiratory Virus Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Region
• 6.2: Emerging Trends in the Global Respiratory Virus Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Respiratory Virus Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Respiratory Virus Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Sanofi
• 7.2: AstraZeneca
• 7.3: Merck
• 7.4: GlaxoSmithKline
• 7.5: Serum Institute of India
• 7.6: Moderna
• 7.7: Bavarian Nordic